Symbols

NMTC

NeuroOne Medical·NASDAQ

--(--)

NMTC fundamentals

NMTC Q1 2026 Earnings

NeuroOne Medical (NMTC) released its earnings on Feb 17, 2026: revenue was 2.89M (YoY -54.08%), met estimates; EPS was -0.03 (YoY -150.00%), met estimates.

Revenue / YoY

2.89M

-54.08%

EPS / YoY

-0.03

-150.00%

Report date

Feb 17, 2026

NMTC Earnings Call Summary for Q1,2026

Revenue Growth: FY2026 sales target of $10.5 million (17% YoY), Q1 2026 sequential sales increase of 5.5%.
Product Adoption: OneRF ablation system achieved nearly half of total cases since launch; trigeminal system treated 9 patients with 100% pain relief.
Strategic Momentum: Drug delivery program accelerated to Q3 2026 launch; strategic partnership discussions for trigeminal system.
Financial Health: Gross margin improved to 54.2%, cash position sufficient for FY2026 operations.
Pipeline Expansion: Lower back pain programs in development, with advisory board formation and manufacturing partnerships.

Earnings

EPS

Revenue

Revenue & Expenses

NMTC has released its 2026 Q1 earnings report, with revenue of 2.89M, reflecting a YoY change of -53.90%, and net profit of -1.44M, showing a YoY change of -180.54%. The Sankey diagram below clearly presents NMTC's revenue sources and cost distribution.

Key Indicators

NeuroOne Medical (NMTC) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

NeuroOne Medical (NMTC)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

NeuroOne Medical (NMTC)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

NeuroOne Medical (NMTC)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown